Algorhythm Holdings Inc (RIME) Q1 2026 Earnings Call Transcript

Why It Matters

The accelerated top‑line growth and margin expansion position iRhythm to capture a larger share of the expanding long‑term cardiac monitoring market and to fund strategic AI and international initiatives, while regulatory clarity will be pivotal for sustained profitability.

Key Takeaways

• Revenue up 26% YoY to $199.4 million.
• Adjusted EBITDA margin improves 880 bps to 7.1%.
• Free cash flow negative $33M, but cash balance $550M.
• EHR integration now drives 53% of total volume.
• Guidance raised to $875‑$885M, EBITDA margin 12‑13%.

Pulse Analysis

The cardiac monitoring sector is undergoing a shift toward longer‑duration, data‑rich diagnostics, and iRhythm is capitalizing on that trend. In Q1 2026 the company posted a 26% revenue surge, outpacing the modest rise in operating expenses, thanks to sustained volume growth across ZioMonitor and Zio AT. Manufacturing automation lifted gross margins by 210 basis points, while operating leverage drove an 880‑basis‑point jump in adjusted EBITDA margin. This financial momentum underpins a raised full‑year outlook of $875‑$885 million, signaling confidence in both market demand and execution efficiency.

Strategically, iRhythm is deepening its foothold in primary care and expanding workflow integration. Over half of all monitoring volume now flows through electronic health‑record‑integrated accounts, and three‑quarters of its top 100 customers are integrated, enhancing clinician adoption and data continuity. The firm’s AI platform, built on more than 3 billion curated ECG hours, is delivering predictive pilots with over 85% accuracy, positioning the company to move upstream in patient pathways. Internationally, record performance in the U.K. and a new reimbursement supplement in Japan illustrate growing global traction, while the upcoming 2027 Mobile Cardiac Telemetry (MCT) launch promises to broaden the addressable market.

Regulatory and compliance considerations remain a focal point. Although iRhythm has remediated the FDA warning letter and a third‑party review found no material quality issues, the company continues to cooperate with a DOJ civil investigative demand, adding a layer of uncertainty. Nonetheless, the firm’s proactive regulatory roadmap—including a separate 510(k) submission for its next‑generation algorithm—aims to secure approvals ahead of the 2027 MCT rollout. Investors should weigh the upside from expanding AI capabilities and international markets against the residual risk of regulatory outcomes, which could materially affect the company’s growth trajectory.